A carregar...
Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance
Trastuzumab is an antibody-based therapy drug targeting HER2-overexpressing tumors. While it has been proven to be very successful initially, most patients eventually develop resistance to trastuzumab. The mechanism of drug resistance is not well understood. Identifying pathways that mediate trastuz...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5542228/ https://ncbi.nlm.nih.gov/pubmed/28507275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17415 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|